- Author: Kathy Keatley Garvey
Sotelo, a researcher in the laboratory of molecular geneticist and physiologist Joanna Chiu, professor and vice chair of the UC Davis Department of Entomology and Nematology, will speak at 4:10 p.m. Plans are to record the seminar for later viewing.
In his abstract, Sotelo relates: “As genome association technologies improve, we have more information regarding the genetic components underlying neurodegenerative and neuropsychiatric disorders such as Alzheimer's, Parkinson's, and schizophrenia. Drosophila melanogaster offers a genetically tractable in vivo system that can be used to perform genetic screens and characterization of genes associated with complex disorders. By combining physiological and behavioral analyses, my work aims to understand the molecular mechanism and neuronal networks involved in some of these conditions.”
“Schizophrenia is a condition that is characterized by its debilitating and poorly understood symptoms," he pointed out. "By studying the genetic component of this disorder, we aim to untangle the mechanisms behind those symptoms. This could potentially help us to develop new and more effective treatments. Using a similar approach would give us insights better understanding of others disorders like Alzheimer's and Parkinson's.”
Said Professor Chiu: “Sergio's exciting thesis research highlights the value of Drosophila as an animal model to study biological processors. To many, it is probably surprising to hear that this tiny insect is constantly used as an animal model to study complex human diseases such as Alzheimer's and Parkinson's. In fact, there are quite a number of similarities between fly and human physiological systems, even in the brain.”
Sotelo joined the Chiu lab as a postdoctoral fellow in the summer of 2020. “Despite the difficult situation brought on by COVID, Sergio is making significant progress in his research on biological rhythms," Chiu said. "He has brought his expertise in neurogenetics, infused the lab with creative energy, and contributed to the training and growth of younger investigators in the lab. Recently, he was named a Pew Latin American Fellow in the Biomedical Sciences, a prestigious award for a well-deserved scientist.”
A native of Puente Alto, Santiago, Chile, Sotelo is one of 10 post-docs from across Latin America—including Argentina, Brazil, Chile, Mexico, Peru, and Uruguay—to receive two years of funding to conduct research. The fellows work under the mentorship of prominent biomedical scientists, including alumni of the Pew Scholars Program in the Biomedical Sciences.
The UC Davis Department of Entomology and Nematology seminars are held on Wednesdays at 4:10 p.m. and include both in-person and virtual lectures. All in-person seminars are held in 122 Briggs Hall, while the virtual seminars are broadcast on Zoom. For more information, contact seminar coordinator Shahid Siddique, at ssiddique@ucdavis.edu.
![One of the illustrations that Sergio Hidalgo Sotelo will present in his seminar. One of the illustrations that Sergio Hidalgo Sotelo will present in his seminar.](https://ucanr.edu/blogs/entomology/blogfiles/86560.jpg)
- Author: Kathy Keatley Garvey
An enzyme inhibitor developed in the UC Davis laboratory of Bruce Hammock and tested in mice by a team of international researchers shows promise that it could lead to a drug to prevent or reduce the disabilities associated with the neurodevelopmental disorders of autism and schizophrenia.
“We discovered that soluble epoxide hydrolase (sEH) plays a key role in inflammation associated with neurodevelopmental disorders. Inhibiting that enzyme stops the inflammation and the development of autism-like and schizophrenia-like symptoms in animal models,” said collaborator Kenji Hashimoto, a professor with the Chiba University Center for Forensic Mental Health, Japan. The scientists found higher levels of sEH in a key region of the brain—the prefrontal cortex of juvenile offspring-- after maternal immune activation (MIA).
“Mothers who have MIA, which results from severe stress in that region of the brain, have an increased occurrence of neurodevelopment disorders in their offspring,” Hashimoto explained. “In our study, the sEH enzyme increased dramatically in a key brain region of mice pups from mothers with MIA.”
The research, published today (March 18) in the Proceedings of the National Academy of Sciences (PNAS), is the work of 14 researchers from Chiba University Center for Forensic Mental Health; the Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, in Wako, Saitama, Japan; and the Hammock laboratory.
Research in Mice Pups
By inhibiting sEH, the researchers reversed cognitive and social interaction deficiencies in the mice pups. They hypothesize that this is due to increasing natural chemicals, which prevent brain inflammation. In people, this could reduce the disabilities associated with autism, such as anxiety, gastrointestinal disturbances and epilepsy.
“The same chemical and biochemical markers behaved as predicted in human stem cells,” said Hammock, a distinguished professor who holds a joint appointment with the Department of Entomology and Nematology and the UC Davis Comprehensive Cancer Center.
Earlier studies have indicated a genetic disposition to the disorders. The team also studied postmortem brain samples from autism patients that confirmed the alterations.
“In the case of both autism and schizophrenia, the epidemiology suggests that both genetics and environment are contributing factors,” said neuroscientist and associate professor Amy Ramsey of the Department of Pharmacology and Toxicology, University of Toronto, who was not involved in the study. “In both cases, maternal infection is a risk factor that might tip the scales for a fetus with a genetic vulnerability. This study is important because it shows that their drug can effectively prevent some of the negative outcomes that occur with prenatal infections. While there are many studies that must be done to ensure its safe use in pregnant women, it could mitigate the neurological impacts of infection during pregnancy.”
Neuroscientist Lawrence David, professor and chair of the School of Public Health, University of Albany, N.Y., who was not involved in the research, said that the study might lead to “an important therapeutic intervention for neurodevelopment disorders.”
Might Be Important Therapeutic Invervention
“There is increasing evidence that maternal immune activation activities (MIA) during fetal development can lead to aberrant neurobehaviors, including autistic-like activities,” said Lawrence, who studies neuroimmunology and immunotoxicology. The study “suggests that enzymatic control of fatty acid metabolism is implicated in neuroinflammation associated with schizophrenia and autism spectrum disorders. The expression of Ephx2 giving rise to soluble epoxide hydrolase (sEH) influences production of fatty acid metabolites, which elevate inflammation in the experimental model of mice after MIA; the sEH inhibitor TPPU (N-[1-(1-oxopropyl)-4-piperidinyl]-N'-[4-(trifluoromethoxy)phenyl)-urea) was postnatally used to improved behaviors. Analysis of cadaver brains from individuals with ASD also expressed increased sEH. Fatty acid metabolites have been known to affect fetal development, especially that of the brain; therefore, TPPU might be an important therapeutic intervention for neurodevelopmental disorders.”
Molecular bioscientist Isaac Pessah of the UC Davis School of Veterinary Medicine, distinguished professor and associate dean of research and graduate education in the Department of Molecular Biosciences, described the findings as “significant” and called for more detailed and expanded studies.
“There is mounting evidence that inappropriate maternal immune responses during pregnancy to infection contributes elevated risk to autism spectrum disorder, at least in a fraction of cases,” Pessah said. “The most significant findings reported here is that a commonly used mouse model of immune-triggered behavioral deficits mimicking some of the core symptoms in autistic children can be suppressed by inhibiting a novel biochemical target, soluble epoxide hydrolase; a target not previously explored as a target for therapeutic intervention to treat ASDs. These findings provide a rational basis for more detailed and expanded studies in mice carrying mutations implicated in ASDs to determine whether the therapeutic benefits of soluble epoxide hydrolase inhibitor(s) observed in this study are more generalizable.”
Autism in the United States
The Center for Disease Control and Prevention (CDC) estimates that 1 in 68 children in the United States have autism, commonly diagnosed around age 3. It is four times more common in boys than girls. CDC defines autism spectrum disorder as a “developmental disability that can cause significant social, communication and behavioral challenges.” The disorder impairs the ability to communicate and interact.
Approximately 3.5 million people or 1.2 percent of the population in the United States are diagnosed with schizophrenia, one of the leading causes of disability, according to the Schizophrenia and Related Disorders Alliance of America (SARDAA). Scores more go unreported. Approximately three-quarters of persons with schizophrenia develop the illness between 16 and 25 years of age. Statistics also show that between one-third and one half of all homeless adults have schizophrenia, and 50 percent of people diagnosed have received no treatment. Among the symptoms: delusions, hallucinations, disorganized speech, disorganized or catatonic behavior, and obsessive-compulsive disorders, such as hoarding, according to SARDAA.
Promising Prophylactic or Theraputic Target
In their research paper, titled “Key Role of Soluble Epoxide Hydrolase in the Neurodevelopmental Disorders of Offspring After Maternal Immune Activation,” the scientists described sEH as “a promising prophylactic or therapeutic target for neurodevelopmental disorders in offspring after MIA.”
First author Min Ma and second Qian Ren of the Hashimoto lab conducted the animal and biochemical work, while chemists Jun Yang and Sung Hee Hwang of the Hammock lab performed the chemistry and analytical chemistry. Takeo Yoshikawa, a team leader with the RIKEN's Molecular Psychiatry Laboratory, performed measurements of gene expression in the neurospheres from iPSC (induced pluripotent stem cells) from schizophrenia patients and postmortem brain samples from autism patients.
Hashimoto described the international collaboration as “exciting and productive.” This is their third PNAS paper in a series leading to endoplasmic reticulum stress. “We report discovery of a biochemical axis that leads to multiple neurological disorders, including depression, Parkinson's disease, schizophrenia, autism spectrum disorders and similar diseases,” he said.
First Human Trials
William Schmidt, vice president of clinical development at EicOsis, a Davis-based company developing inhibitors to sEH to treat unmet medical needs in humans and companion animals, said the company is developing a first-in-class therapy for neuropathic and inflammatory pain. “EicOsis is in the process of finalizing our first human trials on the inhibitors of the soluble epoxide hydrolase, originally reported from UC Davis,” Schmidt said. “We are targeting the compounds as opioid replacements to treat peripheral neuropathic pain. It is exciting that the same compound series may be used to prevent or treat diseases of the central nervous system.”
Several grants from the National Institutes of Health, awarded to Hammock, supported the research. Hammock praised the many collaborators and students he has worked with on the project. “This work illustrates the value of research universities in bringing together the diverse talent needed to address complex problems,” Hammock said. “It also illustrates the value of fundamental science. This autism research can be traced directly to the fundamental question of how caterpillars turn into butterflies.”
Now working solely on research to benefit humankind, Hammock began his career in insect science at UC Berkeley where he investigated how epoxide hydrolase degrades a caterpillar's juvenile hormone. The process leads to metamorphosis from the larval stage to the adult insect. Hammock then wondered "Does the enzyme occur in plants? Does it occur in mammals?"
It does, and particularly as a soluble epoxide hydrolase in mammals.
"Science is full of surprises," said Hammock, who founded EicOsis to help human patients conquer pain without opioids. "We need to remember that the concept, the clinical target, and even the chemical structure, came from asking how caterpillars turn into butterflies."
____________________________________________________________________________________________
ABSTRACT, PNAS Paper, "Key Role of Soluble Epoxide Hydrolase in the Neurodevelopmental Disorders of Offspring After Maternal Immune Activation"
“Maternal infection during pregnancy increases the risk of neurodevelopmental disorders such as schizophrenia and autism spectrum disorder (ASD) in offspring. In rodents, maternal immune activation (MIA) yields offspring with schizophrenia- and ASD-like behavioral abnormalities. Soluble epoxide hydrolase (sEH) plays a key role in inflammation associated with neurodevelopmental disorders. Here we found higher levels of sEH in the prefrontal cortex (PFC) of juvenile offspring after MIA. Oxylipin analysis showed decreased levels of epoxy-fatty acids in the PFC of juvenile offspring after MIA, supporting increased activity of sEH in the PFC of juvenile offspring. Furthermore, the expression of sEH (or EPHX2) mRNA in iPSC-derived neurospheres from schizophrenia patients with the 22q11.2 deletion was higher than that of healthy controls. Moreover, the expression of EPHX2 mRNA in the postmortem brain samples (Brodmann area 9 and 40) from ASD patients was higher than that of controls. Treatment of TPPU (a potent sEH inhibitor) into juvenile offspring from P28 to P56 could prevent cognitive deficits and loss of parvalbumin (PV)-immunoreactivity in the medial PFC of adult offspring after MIA. In addition, dosing of TPPU to pregnant mothers from E5 to P21 could prevent cognitive deficits, and social interaction deficits and PV-immunoreactivity in the mPFC of juvenile offspring after MIA. These findings suggest that increased activity of sEH in the PFC plays a key role in the etiology of neurodevelopmental disorders in offspring after MIA. Therefore, sEH would represent a promising prophylactic or therapeutic target for neurodevelopmental disorders in offspring after MIA.”
Related Research Published in PNAS
- Soluble Epoxide Hydrolase Plays a Key Role in the Pathogenesis of Parkinson's Disease
- Gene Deficiency and Pharmacological Inhibition of Soluble Epoxide Hydrolase Confers Resilience to Repeated Social Defeat Stress
Contacts:
Bruce Hammock, bdhammock@ucdavis.edu
Kenji Hashimoto, hashimoto@faculty.chiba-u.jp
![UC Davis researchers Jun Yang (left) and Sung Hee Hwang (center) of the Bruce Hammock lab with Bruce Hammock, distinguished professor, who holds a joint appointment with the UC Davis Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center. (Photo by Kathy Keatley Garvey) UC Davis researchers Jun Yang (left) and Sung Hee Hwang (center) of the Bruce Hammock lab with Bruce Hammock, distinguished professor, who holds a joint appointment with the UC Davis Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center. (Photo by Kathy Keatley Garvey)](https://ucanr.edu/blogs/entomology/blogfiles/58912.jpg)
![This is a photo from the Kenji Hashimoto lab, Chiba University Center for Forensic Mental Health, Japan, and includes some of the scientists working on the autism/schizophrenia research. In the center, front row, is Kenji Hashimoto. First author Ma Min, third from right, back row. Second author Qian Ren is in the back row, far right. Researcher Tamaki Ishima is the fourth from right, back row. (Photo courtesy of Kenji Hashimoto lab) This is a photo from the Kenji Hashimoto lab, Chiba University Center for Forensic Mental Health, Japan, and includes some of the scientists working on the autism/schizophrenia research. In the center, front row, is Kenji Hashimoto. First author Ma Min, third from right, back row. Second author Qian Ren is in the back row, far right. Researcher Tamaki Ishima is the fourth from right, back row. (Photo courtesy of Kenji Hashimoto lab)](https://ucanr.edu/blogs/entomology/blogfiles/58913.jpg)